Analysis of clinical medication scheme and nursing measures of acute stress disorder complicated with delirium under the COVID-19

Abstract

Background

COVID-19 is highly contagious, which has a significant impact on people’s physical health and mental health. Under the current COVID-19, some people have negative emotions, such as anger and fear, which have triggered psychological stress, resulting in acute stress disorder of different degrees. Therefore, the study put forward a targeted clinical medication scheme. It applies corresponding nursing measures to explore the role of the targeted medication scheme in improving the mental health and the life quality of patients.

Subjects and Methods

Among the patients with acute stress disorder admitted to our hospital from June 2020 to July 2021, 80 patients with delirium caused by the COVID-19 were selected as research objects according to the medical records and disease analysis. Before using the new clinical medication scheme and nursing measures for treatment, the patients’ delirium and stress disorder were evaluated by Stanford Acute Stress Response Questionnaire (SASRQ) and 3-min Confusion Assessment Scale (3D-CAM). Then the new clinical medication scheme and nursing measures was applied for four weeks, including specific medication for acute stress disorder and delirium, and evaluate the disease status again with the two selected scales.

Results

Table 1 shows the results of SASRQ score and 3D-CAM score of 80 selected patients before and after treatment. The results showed that before treatment, both the SASRQ score and the 3D-CAM score showed that the patient had different degrees of delirium and acute stress disorder. After treatment, both the 3D-CAM score and the SASRQ score of the patient decreased significantly, and the symptoms of acute stress disorder complicated with delirium were significantly improved, with a statistically significant difference (P < 0.05).Table 1.

Results of SASRQ score and 3D-CAM score of 80 patients before and after treatment

Treatment stage	n	SASRQ score	3D-CAM score
Before treatment	80	45.4±2.3	46.5±2.1
After treatment	80	38.6±1.6	39.2±2.5
t	-	21.71	20.00
P	-	0.00	0.00

Conclusions

Under the COVID-19, some people suffer from acute stress disorder and delirium. Therefore, the study put forward a specific clinical medication scheme and nursing measures for these patients, and assessed the acute stress disorder and delirium status before and after treatment through SASRQ and 3D-CAM scales. The results verified the effectiveness of the medication scheme, which had certain clinical application value.